According to a recent purchasing managers' survey, economic activity in the eurozone showed signs of improvement at the beginning of this year, with the rate of decline slowing down compared to previous months. The HCOB Flash Eurozone Composite PMI Output Index, which measures activity in the manufacturing and services sectors, increased to 47.9 in January from 47.6 in December. Economists had expected a reading of 48.0, according to a poll conducted by The Wall Street Journal.
The manufacturing sector saw a notable improvement, with output falling at its slowest rate since April of last year. New orders also declined at a slower pace. Despite disruptions caused by Houthi attacks on shipping in the Red Sea, input costs continued to fall.
HCOB's chief economist, Cyrus de la Rubia, noted that businesses seemed better prepared for disruptions this time around, learning from past experiences. He expressed optimism about the positive start to the year for the Eurozone manufacturing sector.
On the other hand, services experienced its largest decline since October. However, there are positive signs for demand ahead as new business showed improvement.
While France and Germany, the largest economies in the eurozone, posted declines in their respective indexes, the rest of the bloc returned to growth after five months of decline.
Overall, the latest data indicates a cautious improvement in economic activity in the eurozone, with the manufacturing sector leading the way. However, challenges still remain, particularly in the services sector.
Our Latest News
Centaur Media Expects Lower Revenue for Full-Year 2023
Centaur Media expects lower revenue for full-year 2023 due to challenging environment, but surpasses profit margin target through operational improvements.
Summer of Uncertainty: A Mixed Picture for Retailers
This article discusses the mixed outlook for retailers during the uncertain summer season, highlighting both positive and negative trends. It explores the impac...
Novo Nordisk's Semaglutide Reduces Cardiovascular Events in Obesity Trial
Novo Nordisk's obesity treatment, semaglutide (Wegovy), reduces cardiovascular events by 20% in a trial. The drug shows potential for effective weight loss and...